ANDA Litigation Settlements

Winter 2016

GENERICally Speaking: A Hatch Waxman Litigation Bulletin
Case Name Drug Patent No(s). Publicly Available Terms
Novartis Pharms. Corp. v. Amneal Pharms. LLC, 15-1025 (D. Del.) Exelon® Patch (rivastigmine transdermal system)
6,316,023
6,335,031
N/A.
AstraZeneca AB v. Micro Labs USA, Inc., 15-3376, 15-7921 (D.N.J.) Daliresp® (roflumilast tablets)
5,712,298
8,431,154
8,604,064
8,618,142
8,536,206
N/A
Warner Chilcott (US), LLC v. Zydus Pharms. (USA), Inc., 16-0323 (E.D. Tex.) Delzicol® (mesalamine delayed-release capsules)
6,649,180
Zydus and Cadila may market a generic version of Delzicol in the US starting on March 1, 2020, pending FDA approval, or earlier under certain circumstances.

Oren D. Langer

Partner

Managing Partner, New York Office
Member of Executive Board

Ryan M. Schultz

Partner

Pronouns: he/him

Back to Top